- $37.66m
- -$16.42m
- $20.60m
Brief: Scynexis And GSK Resolve Their Disagreement Related To The Restart Of The Phase 3 MARIO Study
Scynexis Inc Expected To Post A Loss Of 19 Cents A Share: Earnings Preview
Brief: SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study
Scynexis Inc Reports Results For The Quarter Ended March 31: Earnings Summary
Scynexis Inc Expected To Post A Loss Of 17 Cents A Share: Earnings Preview
Scynexis Inc Expected To Post A Loss Of 17 Cents A Share: Earnings Preview
Scynexis Inc Expected To Post Earnings Of 3 Cents A Share: Earnings Preview
Brief: Scynexis Q3 EPS USD -0.06
Brief: Scynexis enters into controlled equity offering sales agreement
France's Orano aims to enrich uranium in US in early 2030s, says executive
Scynexis Inc Expected To Post Earnings Of 4 Cents A Share: Earnings Preview
Brief: Scynexis Q2 EPS USD -0.3
Brief: Scynexis To Receive $10 Million Milestone Payment From GSK
Brief: Scynexis Q1 EPS USD 0.01
Scynexis Inc Reports Results For The Quarter Ended In December: Earnings Summary
Scynexis Inc Expected To Post A Loss Of 20 Cents A Share: Earnings Preview
Brief: Scynexis- Co And Glaxosmithkline Intellectual Property Entered Binding MoU
Brief: Scynexis Q3 EPS USD -0.04
Brief: Scynexis Inc Files For Mixed Shelf Of Up To $200 Million- SEC Filing